Hyaluronidase Power Injection Market Size & Share, by Source (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase, Bio-Engineered Hyaluronidase); Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Cosmetology); Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5456
  • Published Date: Dec 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Hyaluronidase Power Injection Market

top-features-companies
    • Argenx SE
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PrimaPharma, Inc.,
    • Halozyme, Inc.
    • Bausch & Lomb Incorporated
    • The Cooper Companies Inc.,
    • Sun Pharmaceutical Industries Ltd.
    • STEMCELL Technologies Inc.
    • Shijiazhuang Yiang Technology Co., Ltd.
    • Calzyme
    • Dermax Medical Technology (Hebei) Co., Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Argenx SE, an international immunology organization that works to modify the lives of people with serious autoimmune diseases, reported affirmative topline information from the Phase 3 ADAPT-SC study testing subcutaneous (SC) efgartigimod (1000 mg efgartigimod-PH20) as a therapy for generalized myasthenia gravis (gMG). Argenx delivered a biologics approval application (BLA) to the US FDA.
  • The Food and Drug Administration (FDA) released a letter sanctioning the emergency utilization of the Alinity m Resp-4-Plex for the coexisting qualitative detection and distinction of RNA from SARS-CoV-2, influenza A virus (flu A), influenza B virus (flu B), and/or Respiratory Syncytial Virus (RSV) in anterior nasal or nasopharyngeal swab specimens accumulated by a healthcare provider (HCP).

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5456
  • Published Date: Dec 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing sharpness across various application fields will majorly drive the market growth of the hyaluronidase power injection market.

The market size of the hyaluronidase power injection market is expected to get a CAGR of approximately 9% over the forecast period, i.e., 2024-2036.

The major players in the market are PrimaPharma, Inc., Halozyme, Inc., Bausch & Lomb Incorporated, The Cooper Companies Inc., Sun Pharmaceutical Industries Ltd., STEMCELL Technologies Inc., Shijiazhuang Yiang Technology Co., Ltd., Calzyme, Dermax Medical Technology (Hebei) Co., Ltd., Takeda Pharmaceuticals Co Limited, Janssen Global Services, LLC, Astellas Pharma Inc., Seagen Inc.

The animal-derived hyaluronidase segment is anticipated to reap the largest market size with almost 55% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying